Pancreatic Cancer Research

LetterPancreatology2025

Letter to the Editor Regarding "A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer: A critical insight".

Journal
Pancreatology
Published
12 June 2025
Citations
0
Type
Letter

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try